Table 6 Relationship between mutation of KRAS gene in exon E2 and clinical parameters
|  | Clinical parameters | No. | KRAS-E2 | Positive rate (%) | χ2 | p value | |
|---|---|---|---|---|---|---|---|
Wild type | Mutant type | ||||||
Age | ≤60 | 112 | 79 | 8 | 7.14 | 0.207 | 0.902 |
>60 | 109 | 75 | 7 | 6.42 | |||
Gender | Male | 114 | 78 | 11 | 9.65 | 3.151 | 0.207 |
Female | 107 | 76 | 4 | 3.74 | |||
Sample type | Tissue sample | 194 | 129 | 14 | 7.22 | 10.462 | 0.033 |
Whole blood sample | 22 | 21 | 0 | 0 | |||
Whole blood + tissue sample | 5 | 4 | 1 | 20.00 | |||
Pathological type | Squamous cell carcinoma | 15 | 12 | 0 | 0 | 5.415 | 0.492 |
Adenocarcinoma | 155 | 104 | 10 | 6.45 | |||
Adenosquamous carcinoma | 7 | 4 | 1 | 14.29 | |||
Staging | Stage IA | 22 | 16 | 0 | 0 | 10.624 | 0.715 |
Stage IB | 51 | 33 | 5 | 9.80 | |||
Stage IIA | 8 | 6 | 0 | 0 | |||
Stage IIB | 9 | 7 | 1 | 11.11 | |||
Stage IIIA | 23 | 16 | 0 | 0 | |||
Stage IIIB | 5 | 4 | 0 | 0 | |||
Stage IV | 33 | 27 | 2 | 6.06 | |||
Treatment | Surgery | 67 | 48 | 4 | 5.97 | 2.406 | 0.879 |
Chemotherapy | 37 | 25 | 1 | 2.70 | |||
Surgery + chemotherapy | 66 | 45 | 6 | 9.09 | |||